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Background
Diagnosis and treatment of latent Tuberculosis infection (LTBI) through screening remains a key public health priority in the elimination of tuberculosis. For over a century, the tuberculin skin test (TST) has been used to diagnose LTBI, despite its many limitations. These include being neither very sensitive, due to anergy in an immunocompromised population, nor specific, due to cross-reactivity in people who are Bacilli Calmette-Guérin (BCG) vaccinated and those who are infected with nontubercular mycobacteria (NTM). [1] Furthermore, TST requires people to return to have their results read, and there is the possibility of error when measuring the size of the induration of the skin reaction. This has led to the development of new in vitro interferon-gamma release assays (IGRAs) aimed at improving the diagnosis for LTBI.
Currently, two IGRAs are commercially available for the diagnosis of LTBI, QuantiFERON Gold Intube (QFT-GIT) (Cellestis Ltd., Carnegie, Australia) and T-SPOT.TB (Oxford Immunotec Ltd, Oxford, UK). IGRAs do not boost responses due to repeated testing, and people are not required to make a second visit to have the results read. [2] These tests offer alternatives for the diagnosis of LTBI, but are more expensive. In the UK, current guidelines recommend the use of IGRAs and/or TST for the diagnosis of LTBI in high risk populations which include children, people who are immunocompromised or at risk of immunosuppression and people from countries with a high incidence of TB. [3] The health economic modelling which underpin these recommendations are based on 'what-if' analyses/scenarios rather than empirical screening evidence [4] and this offers little insight on which diagnostic strategy is the most cost-effective.
Decision makers, such as the National Institute for Health and Care Excellence (NICE), often rely on mathematical modelling to aid in decision making processes, as they are constantly faced with questions on what interventions should be funded. The purpose of modelling is to structure evidence on clinical and economic outcomes in a form that can be used to inform decisions on clinical practices and allocation of resources in order to achieve maximum benefits for health care. [5] Since the introduction of IGRAs, many studies have estimated the cost-effectiveness of various strategies for the diagnosis of LTBI using economic modelling in a decision analytical context. A previous clinical guideline [3] which included a systematic review highlighted that no published studies were identified in these high risk groups. Hence, in this review, the aim is to identify from recent literature the suitability of existing cost-effectiveness models that compared different diagnostic strategies for identifying LTBI in children, immunocompromised or at risk of immunosuppression and people from countries with a high incidence of TB.
Methods
Study eligibility criteria
Citations retrieved were screened by two reviewers (PA and AT) and included in the review if they met the following criteria: Children (immunocompetent), people who are immunocompromised or at risk from immunosuppression (e.g. transplant recipients or HIV) and recent arrivals from countries with a high incidence of TB (≥ 40 cases per 100,000), and comprising a formal economic evaluation involving direct comparison between IGRAs (QFT-G, QFT-GIT or T-SPOT.TB) and TST, and included a decision analytic model.
Search strategy
A search of the literature for published economic evaluations was performed for the purpose of identifying the suitability of existing cost-effectiveness models and their model design.
The cost-effectiveness search was developed and conducted as part of a wider systematic review that aimed to compare both the clinical effectiveness and cost-effectiveness of screening tests (IGRAs and TST) for LTBI in high risk groups. [6] Electronic databases were searched, applying the search strategy to the following databases: MEDLINE, MEDLINE In-Process Citations and Daily Update, [3] which included a systematic review [3] searched for studies published up to 2009, but did not identify any relevant economic modelling studies. Reference lists of potentially relevant articles were manually searched to identify additional studies. Details of search terms are presented in the Appendix.
Study selection
All citations retrieved were screened by two independent reviewers (PA and AT) at title/abstract level, of which potentially relevant publications were further examined for full text. Any disagreements between the reviewers were resolved by a consensus.
Data extraction
Data extraction was conducted by one reviewer (PA) and further cross-checked by a second reviewer (AT). Any disagreements were resolved by discussion or by recourse to a third party reviewer.
Information was extracted on study details (title, author and year of study), baseline characteristics (population, intervention, comparator and outcomes), methods (study perspective, time horizon, discount rate, measure of effectiveness current, assumptions and analytical methods), results (study parameters, base-case and sensitivity analysis results), discussion (study findings, limitations of the models and generalizability) and other (source of funding and conflicts of interests).
Quality assessment
The quality of the studies was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) [7] and the Philips' checklist, [8] respectively. The CHEERS assessment tool comprises of six dimensions which include title and abstract, introduction, methods, results, discussion and other. The Philips' quality assessment tool comprises of two main dimensions, structure of the model and data used to parameterized the model. Study quality was assessed by one reviewer (PA) and cross-checked by a second reviewer (AT).
Data synthesis
Information extracted from the included studies were summarised and presented in Table 1 . These findings were compared narratively, and recommendations for the future modelling of LTBI are discussed.
Results
The literature search identified 8793 records through electronic database searches and other sources.
After removing duplicates, 4020 records were screened for inclusion. On the basis of title and abstract, 3995 records were excluded. The remaining 25 records were included for full-text screening.
A further 15 articles were excluded at the full-text stage, and the reasons for exclusion are shown in Figure 1 . There were no disagreements between the two reviewers, hence the third-party reviewer was not required. The literature search identified ten studies that estimated cost-effectiveness of IGRAs compared with TST in diagnosing LTBI in our three populations of interest, and included a decision analytical model.
Characteristics of included studies
The characteristics of these models are summarised in Table 1 . Four [9] [10] [11] [12] economic evaluations were conducted in Japan, three [13] [14] [15] in the USA and two [3, 4] in the UK, and one [16] in South Africa.
Three studies [9] [10] [11] compared QFT-GIT with TST, two [13, 14] compared IGRA with TST, but have not suggested the type of IGRA being used, one [15] compared QFT-G with TST and four [3, 4, 12, 16] compared various testing strategies (TST, QFT, QFT-GIT, T-SPOT.TB, positive TST followed by QFT and positive TST followed by T-SPOT.TB). A clinical guideline which included an economic model [3] included a no testing strategy. Two [10, 16] economic evaluation were conducted in a child population, six [9, [11] [12] [13] [14] [15] in the immunocompromised population and two [3, 4] in the recently arrived population.
Six [3, [9] [10] [11] [12] [13] studies reported results in terms of cost per quality-adjusted life year (QALY) gained, three studies [4, 15, 16] reported their results in terms of cost per life years saved (LYS), cost per false negative cases of LTBI avoided, cost per TB deaths avoided, cost per reactivation TB avoided or cost per TB avoided and one study [14] was based on number needed to screen to prevent one case of TB.
From the base case results reported, IGRAs tended to be less costly and more effective than other strategies (e.g. TST) in identifying LTBI in these high-risk populations All of the studies included a decision analytical model. The health states included in the models represented those that people would experience while being screened for LTBI. In the model with children, the health states included healthy, LTBI, TB and dead. There was some variation in the health states for the immunocompromised population, due to differences in underlying disease. In the models with recently arrived people, the health states included test results, treatment for LTBI and treatment for TB. One [4] of the model structures was illegible in this population.
Model time horizons ranged from one year to lifetime. In the models with children, the time horizon was lifetime (up to 80-years) with one-year cycle lengths. In the models with immunocompromised cohorts, the time horizons ranged from one-year to lifetime, with three-month or one-year cycle lengths and in the recently arrived cohort, the time horizons ranged from 15-years to 20-years, with annual cycle lengths. Authors suggested that their time horizons were long enough to measure the costs and benefits of these diagnostic strategies. All studies clearly stated and justified their time horizon, cycle lengths and discount rates, where appropriate.
Resource use and costs depended on the perspective taken. All studies clearly stated the perspective/viewpoint of their analyses. Six studies [3, 4, 12, 14, 15] conducted their analyses from the UK NHS or other national health payer perspective, and the remaining four studies [9] [10] [11] 13] conducted their analyses from the societal perspective. The six models that presented results from a health payer perspective included direct costs related to the health service (cost of diagnostic tests, chest x-ray and sputum examinations, treatment for LTBI/ TB and treatment for INH-induced hepatotoxicity). From the four models that presented results based on the societal perspective, three models [9] [10] [11] have not included any indirect costs.
Due to the uncertainty around model input parameters and assumptions made in the models, all authors conducted sensitivity analyses. Five studies [3, 4, [14] [15] [16] ] conducted deterministic (one-and two-way) sensitivity analyses alone. The remaining studies [9] [10] [11] [12] [13] conducted both deterministic and PSAs. Sensitivity analyses were conducted around changing the prevalence of LTBI in these populations, test accuracies of diagnostic tests, cost of IGRAs, return rates for TST and varying the progression rate from LTBI to TB.
Quality assessment of the modelling methods
Structure
The structure of the models were generally of good quality. Studies clearly stated decision problems and objectives of the model, perspective of the analysis and presented model structures which represented the clinical pathway people would follow while being screened for LTBI. However, there were structural concerns identified; three studies [9] [10] [11] have undertaken their analyses from the societal perspective, but have not included indirect costs (e.g. productivity loss) in the analyses. In general, studies stated the location of the analyses, but not their setting, and this may impact on the generalisability of results. Clear, illustrative model structures were presented in majority of the studies except in the Pareek et al. study, where the illustrative structure was illegible.
All authors justified their choice of model structure, which represented the coherent theory of LTBI disease and its treatment. Six studies [9] [10] [11] [12] [13] 16] used decision tree structures with Markov nodes for their analyses, three studies [3, 4, 15] used decision tree structures alone and one study [14] used a Markov model alone. The guideline [3] which comprised of an economic evaluation included a proportion of people returning to have their TST result read. One study [15] included a proportion of people with indeterminate test results on an IGRA, and assumed that people received a second IGRA immediately, but this was not shown in the illustrative structure. All studies included chest x-ray and/or sputum examination to confirm initial active symptomatic TB. All studies included cost of treatment for LTBI/TB. As a result of adhering to treatment, all studies included a proportion of people developing Isoniazid (INH)-induced hepatotoxicity. Other adverse events were not considered.
In the Markov models, similar health states were used to simulate the natural history of LTBI over time.
Data
Methods used to identify information to populate the models were satisfactory. Studies [3, 4, 9, 10, [12] [13] [14] [15] [16] conducted literature reviews, but have not specified the aim of the review. All [3, 4, [9] [10] [11] [12] [13] [14] [15] [16] studies provided references for their model inputs, but were not clear on the choices between data sources or the quality of information used in the models. This might have been a result of a paucity of information in the literature.
Most models [9] [10] [11] [12] [13] [14] [15] [16] used published sources to obtain or derive an estimate of the prevalence of LTBI, but some studies [9, 11, 13, 15] have not elaborated on what the prevalence represents (e.g. prevalence of LTBI in contact tracing, prevalence of LTBI based on occasional screening in the population of interest or prevalence of LTBI that would develop to active TB). Additionally, studies [11-13, 15, 16] using multiple sources were not transparent on the methods to derive the prevalence of LTBI. Test performance for TST and IGRAs were required for the models. Most studies [11-13, 15, 16] conducted literature reviews, and have elaborated on the methods to derive an estimate of sensitivity and specificity. Methods included calculating an estimate based on an average of sensitivity/specificity obtained from the literature and obtaining estimates from meta-analyses. All costs required for the models have been referenced, and where applicable, inflated using the appropriate indices. Authors clearly stated the unit costs used in the models, but some [9] [10] [11] 13] authors have not elaborated on the resource used to estimate the unit costs, especially for the treatment of TB. The perspective of the analyses was stated, but in some studies [9] [10] [11] , the costs did not reflect the viewpoint of the analyses.
All authors [4, [9] [10] [11] [12] [13] [14] 16] , where necessary, discounted costs and benefits using the appropriate rates.
Where results were reported in terms of QALYs, authors [3, [9] [10] [11] [12] [13] provided references used to obtain the utility weights, but have not elaborated on if the source of utility information was relevant to their population.
Uncertainty and assumptions
Uncertainty is unavoidable in economic modelling. Briggs and Gray 1999 [17] and Philips et al. [8] have suggested methods to handle uncertainty. All models have undertaken univariate and multivariate sensitivity analysis on key model input parameters. Four studies [9] [10] [11] [12] have also undertaken probabilistic sensitivity analysis (PSA) for joint parameter uncertainty. In order to have a workable model structure, most studies clearly stated their simplifying assumptions, except the model developed by Kowada 2014; these assumptions were unclear. In general, assumptions outlined appeared to be feasible, but strong in some studies [3, 4, 9] . In the NICE study, [3] authors assumed that people adhered to treatment of LTBI/TB, and it would not lead to any adverse events. Pareek et al. [4] assumed that testing with an IGRA would not lead to an indeterminate result. Kowada 2010 [9] assumed that the chest x-ray is 100% sensitive and specific for diagnosing TB.
Summary of the general approaches to modelling LTBI
Children
Kowada 2012 [10] Kowada 2012 estimated the cost-effectiveness of QFT-GIT compared with TST or chest x-ray for the diagnosis of LTBI in children, using a decision tree structure with Markov nodes. The model started with a hypothetical cohort of children receiving one of three diagnostic strategies and continued with them occupying the LTBI/initial TB or no LTBI health state, characterised by the prevalence of the disease. On positive results, children received a chest x-ray to confirm TB. Children who received a negative result on the chest x-ray were treated for LTBI. Estimates of sensitivity and specificity of tests were obtained from a meta-analysis of developed-country studies. The analysis was conducted from the societal perspective and base-case results were expressed as an incremental costeffectiveness ratio (ICER) based on the outcome of cost per QALY gained. Kowada conducted oneand two-way sensitivity analyses and PSA. The base case results demonstrated that QFT-GIT alone was less costly and more effective than TST alone.
Mandalakas 2013 [16] Mandalakas and colleagues used a decision tree structure with Markov nodes to model young household contacts with an index case. The model started with children (< 5 years) who received one of five diagnostic strategies (no test, TST alone, IGRA alone, TST positive followed by IGRA and TST negative followed by IGRA). Children with positive test results were eligible for treatment for LTBI. Children entered the model at the LTBI health state, and could progress to no infection, initial infection, subsequent infection due to future exposures, pulmonary TB, disseminated TB, TB death or death from other causes. The analysis was conducted from the third-party payer and societal perspectives, and the main results were reported in terms of cost per life-year saved (LYS). Base case results indicated that for 0-2 year olds, the no testing strategy was the dominant strategy whilst for 3-5 year olds, an IGRA following a negative TST was the most effective strategy but not cost-effective compared to no testing.
Immunocompromised
Kowada 2010 [9] Kowada used a decision tree structure with Markov nodes to assess cost-effectiveness of QFT-GIT versus TST in people with rheumatoid arthritis, over a lifetime horizon, starting with a cohort aged 40 years. People with positive/negative results on the TST or positive QFT-GIT received a chest x-ray to diagnose TB, which was assumed to be 100% sensitive and specific. The author provided no comment/discussion on the sources of prevalence of LTBI in this population. Information on the sensitivity and specificity were obtained from a meta-analysis. The primary outcome measure of effectiveness was QALYs gained. The analysis was conducted from the societal perspective and results presented as cost per QALY gained. Kowada conducted one-way and two-way sensitivity analyses and PSA, but the distributions used were not presented. QFT-GIT alone was found to be the most cost-effective strategy, and the base-case results were robust to changes in model input parameters. Kowada suggested that results from the PSA showed that IGRA was the preferred option with 100% probability of being cost-effective compared to TST at a willingness-to-pay of US$50,000 per QALY.
Kowada 2013[11]
Kowada used a decision tree structure with Markov nodes to assess QFT-GIT, TST or chest x-ray in people being screened before haemodialysis, over a lifetime horizon. People with positive results on TST/QFT-GIT received a chest x-ray to detect TB, and were treated accordingly for TB/LTBI. The author assumed that chest x-ray was 100% sensitive and specific. The author conducted a review of the literature, but it was unclear on how the accuracy of the tests were derived. The primary outcome measure of effectiveness was QALYs gained, however, the author has not elaborated on the descriptive tools used to value these health states. The analysis was conducted from the societal perspective and results presented in terms of costs per QALY gained. Kowada conducted one-and two-way sensitivity analyses and PSA, but the distributions and the cost-effectiveness acceptability curve were not presented. The author demonstrated that QFT-GIT alone was the most cost-effective strategy for the diagnosis of LTBI. presented in terms of cost per QALYs gained. Kowada conducted PSA, and one-and two-way sensitivity analyses. Base-case results showed that positive TST followed by QFT-G was the most cost-effective strategy for occasional screening of women who were non-BCG vaccinated during pregnancy. Results from the PSA showed that the TST followed by QFT-G strategy was the preferred option with 100% probability of being cost-effective at all willingness-to-pay values considered. The results from the sensitivity analyses showed that the base case results were sensitive to changes in the sensitivity of T-SPOT.TB, and the sensitivity of QFT-G in non-BCG vaccinated women.
Laskin et al., 2013 [13] Laskin and colleagues used a decision tree structure with Markov nodes to determine the most costeffective screening strategy in children with new-onset idiopathic nephrotic syndrome. The model starts with children receiving TST/IGRA, and if positive children were eligible for LTBI treatment.
The authors assumed that effective LTBI treatment provided long-term protection against LTBI/TB.
The analyses were conducted from the societal perspective and included indirect costs on travel time and loss of productivity. Base-case results showed that the no screen strategy was less costly and more effective than other strategies. Results from this study should be interpreted with caution because the discounted and undiscounted costs were similar despite the cost-effectiveness being measured over a lifetime horizon. Results were sensitive to changes in the prevalence of LTBI in this population, with the questionnaire followed by IGRA screening strategy to be the most cost-effective strategy at a prevalence of >4.9%. Results from the PSA showed that at a prevalence of 1.1%, no screening compared with IGRA was the preferred screening option, but the authors have not stated at what willingness-to-pay value.
Linas et al., 2011 [14] Linas and colleagues constructed a decision tree structure with Markov nodes and estimated the costeffectiveness of using TST compared with IGRAs in various populations. The model began with a cohort receiving one of three diagnostic strategies (TST alone, IGRA alone or no screening), and showed that the screening strategy no port-of-entry chest x-ray and screening with QFT-GIT was cost-effective with an ICER of approximately £21,600 per case of TB avoided and the no port-ofentry chest x-ray and screening with one-step QFT-GIT was cost-effective, with an ICER of approximately £31,900 per case of TB avoided. These strategies were cost-effective in immigrants whose country of origin had an incidence of TB of 250 per 100,000 and 150 per 100,000, respectively. Sensitivity analyses results showed that increasing the prevalence and progression rate from LTBI to TB increased the cost-effectiveness of using the QFT-GIT. Reducing specificity resulted in the T-SPOT.TB becoming the most cost-effective strategy. Reducing the proportion of immigrants accepting and adhering to LTBI treatment lead to higher cost-effectiveness estimates.
CG117[3]
The authors of CG117 used a decision tree structure and compared four testing strategies: TST, 
Discussion
The evidence-base here offers some insight on the model structures which have been used to assess the cost-effectiveness of IGRAs compared with TST for the diagnosis of LTBI in high risk populations. We identified ten model-based economic evaluations, which mainly used decision tree structures with Markov nodes to simulate people being tested for LTBI, with majority of these models in the immunocompromised population. These results highlight that the evidence available for the other two populations is sparse.
We appraised models against frameworks on best practice for reporting an economic evaluation and economic modelling. In general, all models performed well in terms of reporting quality, and add to existing cost-effectiveness literature, but are subject to limitations. First, majority of the studies indicated the location of the study but have not stated the setting of the analysis and this may limit the generalisability of the results. Second, a majority of the studies used QALYs as their outcome measure and have referenced the source of their utility values, but have not provided commentary on the descriptive tools used to value these health states. When obtaining health state utility values from the literature it is important to consider the methods/tools used to generate these values and their relevance to the population to which they are going to be applied. Third, the perspective of the analysis was stated in all studies, however, some of the resource use and costs reported did not reflect studies' viewpoint. Fourth, studies were transparent about the methods to identify information to populate the models, but it was unclear on any assessment used on the quality of the information.
Finally, all models have explored uncertainty around key model input parameters, but no attempt was made to explore methodological and structural uncertainty, or generalisability. Other concerns relate to the derivation of prevalence, test accuracy and transition probabilities; most studies have not elaborated on these statistical/pre-model analyses.
We identified one study [18] We identified a second systematic review [19] which focussed on the key model input parameters and the methodological differences in studies that assessed the cost-effectiveness of preventative treatment for TB in high risk populations, and not of LTBI diagnosis. In addition, economic models used to assess the cost-effectiveness of strategies for identifying LTBI in a child population were not considered. These authors have outlined the limitations identified in the studies, but have not undertaken a formal quality appraisal of the economic models against the CHEERS [7] or Phillips et al. [8] checklists. Our current review identifies and appraises the economic models that have been used to inform on the diagnosis of LTBI in high risk populations.
For future advances in using economic models to aid in the decision making process for the most costeffective strategy for identifying LTBI in high risk populations, analysts should consider the information required on prevalence of LTBI in these populations, diagnostic accuracy of test(s), and the illustrative model structure. Based on the studies identified, the methods used to derive prevalence, and sensitivity and specificity may not have provided the best estimates, and in some cases might have under/overestimated these input values. As no 'gold standard' test exists for LTBI diagnosis, estimates can be derived from meta-analysing studies that followed-up a cohort of people to the incidence of TB following testing with TST and/or IGRA. For this instance, best estimates would be based on the development of TB as a 'reference standard' for diagnosing LTBI. This method, as opposed to using exposure to TB and test agreement studies alone, may be more appropriate for use in decision analytical models. However, other points ought to be considered: serial testing, BCG vaccination history and anti-tuberculous treatment on testing positive, all of which can have an impact on evaluating test performance. Further discussion of these points are beyond the scope of this paper, but will be addressed in a subsequent manuscript.
The models available provide insight on the clinical pathway should screening for LTBI be undertaken, and which strategy is likely to be cost-effective in high-risk populations. In future models, it will be important to consider which diagnostic strategy is most likely to be cost effective to identify LTBI that progresses to active TB; and not sensitivity and specificity of diagnostic tests aimed at identifying LTBI in general. Such models would incorporate a decision tree structure and epidemiological model to estimate the cost-effectiveness. These models would also provide useful information on an estimate of the number of people who are treated/untreated for LTBI and further developed TB, and any new cases of LTBI.
We undertook a search of the literature to identify all relevant studies that compared TST and IGRAs for identifying LTBI in these three populations of interest. The main strength of this current review is the comprehensive search, reporting quality assessment and data extraction of the relevant information from these studies. Second, it provides a detailed overview and critique of the health economic models that have been used to estimate the cost-effectiveness of IGRAs compared with TST. In terms of limitations, some studies have not reported/presented information on model structure, how prevalence was derived; hence we could not provide a narrative for these studies.
Conclusion
This review highlights the health economic models available on the cost-effectiveness of diagnosing LTBI in high risk populations. The majority of the models were undertaken in an immunocompromised population, which suggests that there is a paucity of evidence available in a child population and recent arrivals population. In general, all models performed well in terms of defining the decision problem, including the study perspective, outlining the choice of comparators, presenting an illustrative model structure and providing a clear outline of the assumptions.
The evidence shows that the models available are based on identifying LTBI in general, and little is known about the cost-effectiveness of diagnostic tests that identify LTBI that progresses to active TB; which shows that research in this area is static. We propose that future pre-model analyses should consider deriving estimates based on the development of TB as a 'reference standard' for diagnosing LTBI in order to inform an economic model. However, the challenge/practicality is to identify prospective longitudinal studies with adequate sample size and a lengthy follow-up in people at high risk of developing TB.
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